ABBV stock, with 24% returns since the beginning of 2024, has marginally underperformed the S&P 500 index, up 27%. An ...

AbbVie's acquisition of Allergan significantly increased the firm's debt level. We expect the firm's net debt position to peak at close to $70 billion in 2020 but given the strong cash flows of AbbVie ...

Equities research analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for Biogen in a research note ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started ... of the total prescription share of the biologics psoriasis market, he said. Of the $4 billion ...

Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Biogen in a research note ...

Humira’s success is down to its incredible versatility – an anti-TNF drug, it is approved in a range of inflammatory diseases, including rheumatoid arthritis, plaque psoriasis and Crohn’s ...

Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic ...

AbbVie Inc.’s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology drugs delivered ...

AbbVie made a change atop its board of directors, naming CEO Robert Michael as chairman on Friday morning. The pharma giant announced that Michael will succeed Richard A. Gonzalez, the former CEO of ...

Humira is a versatile drug used to treat multiple autoimmune diseases, such as rheumatoid arthritis, Crohn’s disease, psoriasis, psoriatic arthritis, ulcerative colitis, and ankylosing spondylitis.